OakLabs GmbH
Société
Onglets principaux
À propos de votre organisation / profil
OakLabs develops biomarker signatures in the context of companion diagnostics (CDx) and precision medicine in order to accurately predict a patient’s response to a specific treatment.
The superior accuracy of our biomarker signatures revives the drug development process for pharma companies: proven 4-fold increase in probability for drug approval as well as cost and
time reduction for clinical trial execution, enabling faster market launch and higher sales during patent protection.
Réseau (0)
Il n'y a pas encore d'organisations dans le réseau.
Cette organisation ne comporte pas d'utilisateur pour le moment.
